NU Skin Enterprises Inc

NU Skin Enterprises Inc(NUS)股票分析

$4.990

+0.308 (+6.17%)收盘时

Loading chart…
最高
5.130
开盘
4.830
成交量加权均价
4.98
成交量
646.13K
市值
536.41M
最低
4.830
成交额
3.22M
企业价值/息税折旧摊销前利润(TTM)
2.16

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others.

AI 分析 of NU Skin Enterprises Inc (NUS)

买入

NU Skin Enterprises Inc (NUS) is a good buy right now, trading at $4.78, which is significantly below its 52-week high of $11.67. The forward P/E ratio is 4.008, indicating potential undervaluation compared to future earnings. Additionally, the stock has shown a recent positive trend with a 5-day change of +1.92% and a 20-day change of +3.24%. However, a key risk is the net margin, which has dropped to -78.03% in Q2 2026, indicating potential ongoing profitability issues that investors should monitor closely.

分析师评级(6)

买入
3 买入
1 持有
2 卖出
当前: 4.99
最低
—
平均
—
最高
—

DA Davidson

2024-12-20

目标价

$7

持有

Citigroup

2024-10-22

目标价

$6.75

持有

DA Davidson

2024-08-12

目标价

$11

持有

Citigroup

2024-08-09

目标价

$12

持有

DA Davidson

2024-05-09

目标价

$13

持有

估值指标

NU Skin Enterprises Inc(NUS)当前预期市盈率为 4.12,5 年平均预期市盈率为 11.03。

预期市盈率

低估
5 年均值 P/E
11.03
当前P/E
4.12
高估
16.12
低估
5.93

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
5.36
当前EV/EBITDA
2.16
高估
8.39
低估
2.34

预期市销率

低估
5 年均值 P/S
0.51
当前P/S
0.16
高估
0.84
低估
0.18

Alphio AI 对 NUS 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%NUS

$6.63

情景价格

基

基准

基准 · 50%NUS

$6.29

情景价格

悲

悲观

悲观 · 25%NUS

$4.75

情景价格

持有 NUS 的大户

C

Castleknight Management LP

+ 持有NUS

-5.48%

3个月收益率

事件时间线

2026-08-10 (ET)

16:30:00

Cuts FY26 Revenue View to $1.28B-$1.35B

16:30:00

Sees Q3 Revenue of $310M to $340M

2026-05-07 (ET)

16:10:00

Company Confirms FY26 Revenue Outlook of $1.35B to $1.5B

16:10:00

Nu Skin Q1 Revenue at $320.6M, Below Estimate

16:10:00

Sees Q2 Revenue of $330M-$360M

资讯

NUS 常见问题 —— 由 Alphio AI 解答

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others. It operates in the Consumer Non-Cyclicals sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

NU Skin Enterprises Inc (NUS) is a good buy right now, trading at $4.78, which is significantly below its 52-week high of $11.67. The forward P/E ratio is 4.008, indicating potential undervaluation compared to future earnings. Additionally, the stock has shown a recent positive trend with a 5-day change of +1.92% and a 20-day change of +3.24%. However, a key risk is the net margin, which has dropped to -78.03% in Q2 2026, indicating potential ongoing profitability issues that investors should monitor closely.

6 analysts cover NUS: 3 rate it Buy, 1 Hold and 2 Sell.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易